Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer’s Disease

Shingo Kakeda; Yukio Miki; Kohsuke Kudo; Harushi Mori; Aya M. Tokumaru; Osamu Abe; Shigeki Aoki; Working Group for Brain MRI Guidelines for Anti-Aβ Antibody Treatment from The Japan Radiological Society, The Japanese Society for Neuroradiology, and The Japanese Society for Magnetic Resonance in Medicine

doi:10.2463/mrms.gl.2025-1000

Shingo Kakeda , Yukio Miki, Kohsuke Kudo, Harushi Mori, Aya M. Tokumaru, Osamu Abe, Shigeki Aoki, Working Group for Brain MRI Guidelines for Anti-Aβ Antibody Treatment from The Japan Radiological Society, The Japanese Society for Neuroradiology, and The Japanese Society for Magnetic Resonance in Medicine

Author information

Shingo Kakeda Corresponding author
Department of Radiology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan
Yukio Miki
Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Kohsuke Kudo
Department of Diagnostic Imaging, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
Harushi Mori
Department of Radiology, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan
Aya M. Tokumaru
Department of Diagnostic Radiology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
Osamu Abe
Department of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Shigeki Aoki
Department of Neurophysiology, Juntendo University School of Medicine, Tokyo, Japan
Working Group for Brain MRI Guidelines for Anti-Aβ Antibody Treatment from The Japan Radiological Society, The Japanese Society for Neuroradiology, and The Japanese Society for Magnetic Resonance in Medicine

Keywords: Alzheimer’s disease, amyloid-related imaging abnormalities, anti-amyloid beta antibody treatment, brain, guidelines, magnetic resonance imaging

JOURNAL OPEN ACCESS Advance online publication
Supplementary material

Article ID: gl.2025-1000

DOI https://doi.org/10.2463/mrms.gl.2025-1000

Details

Abstract

Purpose: These guidelines aim to support MRI diagnosis in patients receiving anti-amyloid β (Aβ) antibody treatment without restricting treatment eligibility.

Materials and Methods: These guidelines were collaboratively established by Japan Radiological Society, The Japanese Society of Neuroradiology, and Japanese Society for Magnetic Resonance in Medicine by reviewing existing literature and the results of clinical trials.

Results: Facility standards should comply with the “Optimal Use Promotion Guidelines” of Japan, and physicians should possess comprehensive knowledge of amyloid-related imaging abnormalities (ARIA) and expertise in brain MRI interpretation. The acquisition of knowledge regarding amyloid-related imaging abnormalities, brain MRI, anti-Aβ antibody introduction, and post-treatment diagnosis are also recommended.

Conclusion: These guidelines facilitate the accurate diagnosis and effective management of ARIA; ensure the safe administration of anti-Aβ drugs; and provide a framework for MRI facilities, includes staffing requirements and the use of MRI management systems.

Corresponding author

Register with J-STAGE for free!